InVivoPlus anti-mouse PD-1 (CD279)

Catalog number: BP0146_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 3662.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoPlus anti-mouse PD-1 (CD279)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Neutralisation/Blocking
Species: Mouse
Host: Rat
Clonality: Monoclonal
Isotype: IgG2a Kappa
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: RMP1-14
Related products: 
Related products: Recommended Isotype Control(s): InVivoPlus rat IgG2a isotype control (BP0089)
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer (IP0070)
Additional information: 
Synonyms: RMP1-14; BP0146; Pdcd1; Pdc1; PD-1; Ly101; protein PD-1; programmed cell death protein 1; mPD-1; programmed cell death 1; BioXCell
Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22(12):1402-1410. Read more
Zelenay S, Van der veen AG, Böttcher JP, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162(6):1257-70. Read more
Ngiow SF, Young A, Jacquelot N, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75(18):3800-11. Read more
Zander RA, Obeng-adjei N, Guthmiller JJ, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17(5):628-41. Read more
Vanpouille-box C, Diamond JM, Pilones KA, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75(11):2232-42. Read more
Twyman-saint victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-7. Read more
Evans EE, Jonason AS, Bussler H, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015;3(6):689-701. Read more
Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74(14):3652-8. Read more
Mcgray AJ, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22(1):206-18. Read more
John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636-46. Read more